Compare

Claritev Corporation/$CTEV

1D1W1M3M6MYTD1Y5YMAX

About Claritev Corporation

Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The company's focus is on being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
Ticker
$CTEV
Sector
Health
Primary listing
NYSE
Employees
3,000
Headquarters
McLean, United States
Website
www.claritev.com

CTEV Metrics

BasicAdvanced
$407M
-
-$16.99
0.89
-

Bulls say / Bears say

Revenue rose 6.6% year on year in Q2, and Claritev raised its 2026 revenue and adjusted EBITDA guidance. Quarterly free cash flow also improved to $54.6 million from $36.6 million a year earlier. (SEC)
Bookings topped $70 million in the first half, putting the company on track towards its $100 million full-year target. The expanded Marpai agreement shows Claritev can cross-sell payment-integrity services beyond its existing network relationship. (SEC, Claritev)
The DOJ closed its antitrust grand-jury proceeding and confirmed Claritev was not under criminal investigation, removing one source of legal uncertainty. The company has also won a role supporting a nationwide provider network for the World Trade Center Health Program, extending its reach into public-sector healthcare. (SEC, Claritev)
Claritev carried about $4.6 billion of debt at June 2026 and paid roughly $100 million in quarterly interest, contributing to a $59.2 million Q2 net loss. Unrestricted cash was only $14.4 million and full-year free cash flow guidance was $5 million to $15 million. (SEC, SEC)
The DOJ’s criminal proceeding is closed, but a separate civil inquiry remains open, and provider antitrust litigation is progressing. Recent court rulings favouring providers could increase the risk of costly claims and reputational damage. (SEC, HFMA)
Growth is concentrated: one client accounted for 35% of Q2 revenue, while network and payment-integrity revenue fell 7.0% and 5.9%, respectively. Adjusted EBITDA margin also narrowed to 60.5% from 63.8%, leaving results exposed if the leading claims business slows. (SEC, SEC)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.

CTEV Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

CTEV Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

CTEV News

AllArticlesVideos

Claritev Q2 Earnings Call Highlights

MarketBeat3 months ago

Claritev Corporation Reports Second Quarter 2026 Results

Business Wire3 months ago

Funds containing CTEV

Funds
Fund name
Fund size
$CTEV weighting
SPDR Russell 2000 US Small Cap£R2SC
$5.3B0.01%
SPDR Russell 2000 US Small Cap€R2US
$5.3B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.